Opposite prognostic significance of cellular and serum circulating microRNA-150 in patients with chronic lymphocytic leukemia

Molecular Medicine

Volumn 21, Issue , 2015, Pages 123-133

  Stamatopoulos, Basile ^a   Van Damme, Michaël ^a   Crompot, Emerence ^a   Dessars, Barbara ^b   El Housni, Hakim ^b   Mineur, Philippe ^c   Meuleman, Nathalie ^a   Bron, Dominique ^a   Lagneaux, Laurence ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c Service des urgences Grand Hôpital de Charleroi   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD19 ANTIGEN; CD23 ANTIGEN; CD38 ANTIGEN; LIPOPROTEIN LIPASE; MICRORNA; MICRORNA 150; PROTEIN KINASE ZAP 70; SOLUBLE CD23 ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; MIRN150 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; BINET STAGE; BLOOD LEVEL; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CELL LEVEL; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; EXOSOME; EXTRACELLULAR SPACE; FOLLOW UP; GENE EXPRESSION REGULATION; GENE LOCATION; GENE OVEREXPRESSION; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; LYMPHOCYTE DOUBLING TIME; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MEMBRANE MICROPARTICLE; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE; TREATMENT FREE SURVIVAL; TUMOR VOLUME; UPREGULATION; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; EXOSOMES; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTOSIS; MICRORNAS; MIDDLE AGED; PROGNOSIS; RECURRENCE; TUMOR BURDEN;

EID: 84935877439     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2014.00214     Document Type: Article

References (33)

1. Herishanu Y, Katz BZ, Lipsky A, Wiestner A. (2013) Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol. Oncol. Clin. North Am. 27:173-206.
2. Hamblin T. (2002) Chronic lymphocytic leukaemia: one disease or two? Ann. Hematol. 81:299-303.
3. Van Bockstaele F, Verhasselt B, Philippe J. (2009) Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 23:25-47.
4. Fabbri M, et al. (2008) MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia. 22:1095-105.
5. Bartel DP. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281-97.
6. Chen CZ. (2005) MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med. 353:1768-71.
7. Weber JA, et al. (2010) The microRNA spectrum in 12 body fluids. Clin. Chem. 56:1733-41.
8. Vickers KC, Remaley AT. (2012) Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 23:91-7.
9. Arroyo JD, et al. (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 108:5003-8.
10. Rosell R, Wei J, Taron M. (2009) Circulating MicroRNA signatures of tumor-derived exosomes for early diagnosis of non-small-cell lung cancer. Clin. Lung Cancer. 10:8-9.
11. Gilad S, et al. (2008) Serum microRNAs are promising novel biomarkers. PLoS One. 3:e3148.
12. Pritchard CC, et al. (2012) Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev. Res. (Phila). 5:492-7.
13. Mitchell PS, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105:10513-8.
14. Moussay E, et al. (2011) MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 108:6573-8.
15. He Y, Jiang X, Chen J. (2014) The role of miR-150 in normal and malignant hematopoiesis. Oncogene. 24;33:3887-93.
16. Fulci V, et al. (2007) Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 109:4944-51.
17. Mraz M, et al. (2014) MicroRNA-150 contributes to the proficiency of B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1 genes. Blood. 124:84-95.
18. Wang M, et al. (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J. Pathol. 215:13-20.
19. Papakonstantinou N, et al. (2013) Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol. Med. 19:115-23.
20. Stamatopoulos B, et al. (2007) Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Clin. Chem. 53:1757-66.
21. Stamatopoulos B, et al. (2009) microRNA-29c and microRNA-223 down-regulation has in vivo sig-nificance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 113:5237-45.
22. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. (2011) Analysis of circulating microRNA: preanalytical and analytical challenges. Clin. Chem. 57:833-40.
23. Stamatopoulos B, et al. (2010) A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. PLoS One. 5:e12780.
24. Ferrajoli A, et al. (2013) Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic leukemia. Blood. 122:1891-9.
25. Budoni M, et al. (2013) The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles. Cell Transplant. 22:369-79.
26. Mahaweni NM, Kaijen-Lambers MEH, Dekkers J, Aerts JGJV, Hegmans JPJJ. (2013) Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma. J. Extracell. Vesicles. 2:22492.
27. Rassenti LZ, et al. (2008) Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 112:1923-30.
28. Ito M, et al. (2014) MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6 in advanced cutaneous T-cell lymphoma. Blood. 123:1499-511.
29. Wang M, Yang W, Li M, Li Y. (2014) Low expression of miR-150 in pediatric intestinal Burkitt lymphoma. Exp. Mol. Pathol. 96:261-6.
30. Yokobori T, et al. (2013) MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci. 104:48-54.
31. Sun Y, et al. (2013) Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features. Oncol. Rep. 29:704-12.
32. Ma Y, et al. (2012) miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 61:1447-53.
33. Mraz M, et al. (2009) miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 23:1159-63.